Project Grant DP2AI192583
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
- This Project Grant award titled "Epitranscriptomic Regulation of Microglia in Alzheimer's Disease" was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University. The $509,413 grant, awarded on September 15, 2025, will support research to understand the role of epitranscriptomic regulation, specifically the m6A modification, in controlling microglial function and its contribution to Alzheimer's disease pathogenesis. The project aims to elucidate how...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $492,494 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, for a research project titled "Inflammation and Plaque Formation Downstream of Disrupted Autophagy in Alzheimer's Disease". The funding, awarded on December 1, 2024 with an ultimate completion date of...
- The federal Project Grant award of $3,204,624.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, supports research to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The research aims to provide essential insight for developing improved therapeutics to reduce human sepsis, as well as immune adjuvants to enhance host...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) for $124,050 supports research to elucidate the molecular mechanisms underlying synapse loss in Alzheimer's disease (AD). The award will fund the development of a novel pooled CRISPR screening platform to systematically investigate regulators of synaptic phosphatidylserine (PS) exposure, a key driver of glial-mediated synapse removal in AD models. Specifically, the research aims to determine how IL-6 and...
- The National Institute on Aging awarded The Johns Hopkins University a $622,086 Project Grant on May 15, 2025 under the Aging Research federal grant program (CFDA 93.866) to elucidate the mechanisms driving microglial activation by amyloid-beta oligomers and assess the involvement of the NOD2/RIPK2 signaling pathway in neuroinflammation and neurodegeneration in Alzheimer's disease. The project aims to characterize the role of NOD2/RIPK2 signaling in Alzheimer's disease and explore its...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), has awarded a $429,000 project grant to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to support research on the role of Alzheimer's disease risk genes in neural function, degeneration, and synapse organization. The project aims to examine how specific mutations in the PSEN1 gene, which are linked to early-onset familial Alzheimer's disease, influence adult...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $487,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pennsylvania on Aug 15, 2025. The grant supports research to develop an in vivo CRISPR screening platform to identify genetic regulators of microglial phagocytosis in Alzheimer's disease (AD). Key objectives include: By leveraging recent advancements in hematopoietic stem cell gene editing, barcoding, and microglial transplantation, the research aims to uncover novel therapeutic targets to enhance microglial function and develop more effective treatments for AD. The project will run for 5 years until its ultimate completion date of Jul 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $487.5k | 8/15/25 |